Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.
Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior
…
340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.
On Monday, the justices heard the case of
…
Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in
…
The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.
Arguments in American Hospital Association v. Becerra are due
…
U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.
Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he
…
The U.S. Health Resources and Services Administration (HRSA) said this morning it “respectfully disagrees with” and “continues to evaluate its options” about a federal district judge’s Nov. 5 finding that drug manufacturers Novartis and United Therapeutic’s 340B contract pharmacy policies
…
After a 10-month delay, it looks like we may be getting close to the appointment of a permanent leader of the U.S. Health Resources and Services Administration (HRSA), the federal agency that runs the 340B drug pricing program.
News organization
…
After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in
…
Congressional debate over lowering drug prices has shifted to the U.S. Senate following House passage of the $1.75 trillion Build Back Better social spending bill on Friday.
Congress has been on break this week for the Thanksgiving holiday. It returns
…*Sign up for news summaries and alerts from 340B Report